Jasper Financial Statements From 2010 to 2026

JSPR Stock  USD 1.55  0.04  2.52%   
Jasper Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Jasper Therapeutics' valuation are provided below:
Market Capitalization
44.5 M
Earnings Share
(5.82)
There are over one hundred nineteen available fundamental trends for Jasper Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Jasper Therapeutics' regular fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 8.4 M or Selling General Administrative of 13.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.78. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Jasper Stock
Check out the analysis of Jasper Therapeutics Correlation against competitors.
To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Jasper Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets67.4 M91.9 M45.4 M
Slightly volatile
Other Current Liabilities12.2 M11.6 M3.9 M
Slightly volatile
Total Current Liabilities8.9 M17.5 M5.5 M
Slightly volatile
Other Liabilities2.2 M2.3 M4.5 M
Very volatile
Net Tangible Assets57.6 M32.4 M78.4 M
Slightly volatile
Warrants69 M71.4 M86.4 M
Slightly volatile
Accounts Payable2.9 M4.6 M1.7 M
Slightly volatile
Cash60.2 M82.4 M42.1 M
Slightly volatile
Non Current Assets Total4.6 M4.7 M2.1 M
Slightly volatile
Non Currrent Assets Other920.3 K943 K430.3 K
Slightly volatile
Cash And Short Term Investments60.2 M82.4 M42.1 M
Slightly volatile
Common Stock Total Equity2.4 K4.6 K1.6 K
Slightly volatile
Common Stock Shares Outstanding17.6 M16.8 M3.9 M
Slightly volatile
Short Term Investments80.1 M90.1 M98.4 M
Slightly volatile
Liabilities And Stockholders Equity67.4 M91.9 M45.4 M
Slightly volatile
Non Current Liabilities Total2.6 M2.7 M7.6 M
Pretty Stable
Capital Surpluse81.2 M162.3 M50.9 M
Slightly volatile
Other Stockholder Equity365.3 M347.9 M91 M
Slightly volatile
Total Liabilities18.1 M16.4 M13.3 M
Slightly volatile
Long Term Investments110.3 M115.4 M101.7 M
Slightly volatile
Total Current Assets62.7 M87.2 M43.3 M
Slightly volatile
Non Current Liabilities Other1.9 MMM
Very volatile
Common Stock2.9 K1.8 K6.9 K
Slightly volatile
Short and Long Term Debt Total2.8 M2.1 MM
Slightly volatile
Property Plant And Equipment Net4.3 M3.3 M2.8 M
Slightly volatile
Long Term Debt10.5 M11.8 M12.9 M
Slightly volatile
Net Receivables213.8 K225 K552.7 K
Slightly volatile
Long Term Debt Total10.5 M11.8 M12.9 M
Slightly volatile
Capital Lease Obligations2.8 M2.1 MM
Slightly volatile
Property Plant And Equipment Gross5.6 M7.7 M3.5 M
Slightly volatile
Capital Stock1.9 K1.8 K1.5 K
Slightly volatile
Net Working Capital59 M69.7 M33.2 M
Slightly volatile
Property Plant Equipment3.8 M4.1 M2.7 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.8 M
Slightly volatile
Short Term Debt943.5 K1.3 M657.8 K
Slightly volatile

Jasper Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.2 M4.4 M
Pretty Stable
Selling General Administrative13.1 M23.5 M6.9 M
Slightly volatile
Other Operating Expenses47.4 M87.7 M25.6 M
Slightly volatile
Research Development34.3 M64.2 M18.7 M
Slightly volatile
Total Operating Expenses47.4 M87.7 M25.6 M
Slightly volatile
Cost Of Revenue963.2 K1.6 M419.4 K
Slightly volatile
Net Interest IncomeM5.8 M1.7 M
Slightly volatile
Interest IncomeM5.8 M1.7 M
Slightly volatile
Selling And Marketing Expenses886.4 K997.2 K1.1 M
Slightly volatile

Jasper Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings61.6 K64.8 K911 K
Slightly volatile
Stock Based CompensationM7.6 MM
Slightly volatile
Begin Period Cash Flow105.4 M100.4 M27.3 M
Slightly volatile
Depreciation837.1 K1.6 M610.3 K
Slightly volatile
Capital Expenditures472 K496.8 K1.9 M
Slightly volatile
Total Cash From Financing Activities53.2 M55.1 M38.9 M
Slightly volatile
End Period Cash Flow60.5 M82.9 M42.2 M
Slightly volatile
Change To Liabilities442.5 K465.8 K667 K
Very volatile
Issuance Of Capital Stock59.9 M54.3 M29.3 M
Slightly volatile
Other Cashflows From Investing Activities17.1 K18 K135.1 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.440.464.6627
Slightly volatile
Cash Per Share5.375.65104
Slightly volatile
Income Quality0.660.790.5869
Slightly volatile
Net Debt To EBITDA1.411.071.8985
Slightly volatile
Current Ratio8.775.7210.8799
Slightly volatile
Capex Per Share0.04140.04351.5227
Slightly volatile
Interest Debt Per Share0.140.12436.3568
Slightly volatile
Debt To Assets0.05020.02610.0588
Slightly volatile
Price Earnings To Growth Ratio0.20.190.0617
Slightly volatile
Ebt Per Ebit1.11.081.0434
Pretty Stable
Quick Ratio8.775.7210.8799
Slightly volatile
Cash Ratio8.485.4110.7544
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0689
Very volatile
Debt Ratio0.05020.02610.0588
Slightly volatile

Jasper Fundamental Market Drivers

Jasper Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Jasper Therapeutics Financial Statements

Jasper Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Jasper Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Jasper Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Jasper Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue1.6 M963.2 K

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Jasper Stock

  0.68XBIO Xenetic BiosciencesPairCorr

Moving against Jasper Stock

  0.71ARDX Ardelyx Sell-off TrendPairCorr
  0.64JRVR James River GroupPairCorr
  0.63CUB Lionheart HoldingsPairCorr
  0.57LION Lionsgate Studios HoldingPairCorr
  0.56UPB Upstream BioPairCorr
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.